|
|
121 Beiträge ausgeblendet. |
|
mit Cell; das dauert wohl noch ein weilchen - mit Sicherheit ein interessanter Wert - der wohl in jeder W - Liste gut aufgehoben ist -
die brauchen natürlich noch starke Partnerschaften damit Sie Ihre Phase 3 auch bezahlen können - da kommt noch einiges an Kosten auf die zu - Tippe auch auf weitere Kapitalerhöhungen - im Moment verbrennen die ja so schon sehr viel Geld - 2010 sind es 147MIo gewesen und 2009 waren es 117 Millionen
Gruß galway
Der Anfang einer vielseitigen Präsentation-Show durch die Staaten beginnt
link: www.thestreet.com/story/11017198/1/...re-conference.html
Date(s): 17-Mar-2011 7:36 AM
For a complete listing of our news releases, please click here
CAMBRIDGE, Mass., Mar 17, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it has
elected to exercise its option with Merck & Co., Inc., to co-promote
ridaforolimus, an investigational mTOR inhibitor, in the sarcoma
indication upon its potential approval in the United States next year.
Based on the terms of the license agreement that ARIAD and Merck entered
into in May 2010 for the development, manufacture and commercialization
of ridaforolimus in oncology, ARIAD has the option to co-promote
ridaforolimus with up to 20 percent of the sales effort for the product
in all indications in the U.S., and Merck will compensate ARIAD for its
sales efforts.
"The decision to co-promote ridaforolimus upon potential launch in 2012
is consistent with our plans to build a fully integrated commercial
oncology company and dovetails with the potential launch of ponatinib,
our investigational pan-BCR-ABL inhibitor, in patients with resistant or
intolerant chronic myeloid leukemia in late 2012 or early 2013," stated
Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD.
"By co-promoting ridaforolimus in the U.S., ARIAD will contribute to its
commercial success in the sarcoma indication, gain important commercial
experience in oncology prior to ponatinib's potential approval and
maintain close visibility on Merck's progress and plans for
commercializing ridaforolimus in other cancer indications," he added.
Details of the co-promotion will be finalized in a co-promotion
agreement to be negotiated by ARIAD and Merck. Merck has indicated its
intention to file for marketing approval of ridaforolimus in patients
with metastatic sarcomas this year.
www.tradershuddle.com/20110324190283/...sf-tleo-wdr.html
soeben erschienen
link: www.businesswire.com/news/home/...panion-Diagnostic-Test
ARIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD to Present New Preclinical Data on Ponatinib at the American Association for Cancer Research Annual Meeting
Date(s): 29-Mar-2011 7:36 AM
For a complete listing of our news releases, please click here
CAMBRIDGE, Mass., Mar 29, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new
preclinical data on ponatinib,
the company's investigational multi-targeted tyrosine kinase inhibitor,
will be presented at the American Association for Cancer Research (AACR)
Annual Meeting to be held April 2-6, 2011 in Orlando, FL.
ARIAD scientist Joseph M. Gozgit, Ph.D., will present the poster
entitled, "Ponatinib (AP24534), a potent pan-FGFR inhibitor with
activity in multiple FGFR-driven cancer models," on Tuesday, April 5,
2011 between 8:00 am and 12:00 pm. The ARIAD poster will be presented
during the session titled "Experimental and Molecular Therapeutics 25"
in Exhibit Hall A4-C, Poster Section 28, Abstract Number 3560.
About ARIAD
ARIAD's vision is to transform the lives of cancer patients with
breakthrough medicines. The Company's mission is to discover, develop
and commercialize small-molecule drugs to treat cancer in patients with
the greatest and most urgent unmet medical need - aggressive cancers
where current therapies are inadequate. ARIAD's product candidate,
ridaforolimus, is an investigational mTOR inhibitor being developed by
Merck that has successfully completed a Phase 3 clinical trial in
patients with soft-tissue and bone sarcomas and is being studied in
multiple cancer indications. ARIAD's second internally discovered
product candidate, ponatinib, is an investigational pan-BCR-ABL
inhibitor in a pivotal Phase 2 clinical trial in patients with chronic
myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional
information, please visit www.ariad.com.
SOURCE: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208
a bissl wenig.........finde ich
www.streetinsider.com/Analyst+Comments/...R/6396703.html
ARIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD to Present at the Leerink Swann Cancer Roundtable Conference
Date(s): 31-Mar-2011 7:38 AM
For a complete listing of our news releases, please click here
CAMBRIDGE, Mass., Mar 31, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the Leerink Swann Cancer Roundtable Conference being held at
the Roosevelt Hotel in New York City, New York on Thursday, April 7,
2011. Harvey J. Berger, M.D., chairman and chief executive officer at
ARIAD, will provide an overview of the Company's strong oncology
pipeline and progress on its three lead compounds at 3:30 p.m. (ET).
Timothy P. Clackson, Ph.D., president of research and development and
chief scientific officer at ARIAD, will participate on a lymphoma and
leukemia discussion panel at 2:15 p.m. (ET).
Dr. Berger's presentation will be webcast live and can be accessed by
visiting the investor relations section of the Company's website at www.ariad.com/investor.
A replay of the presentation will be available on the ARIAD website
approximately twenty-four hours after the presentation and will be
archived for three weeks.
ARIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors, Demonstrating Inhibition of All FGF Receptor Kinases
Date(s): 5-Apr-2011 7:35 AM
For a complete listing of our news releases, please click here
ORLANDO, Fla. & CAMBRIDGE, Mass., Apr 05, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of
preclinical studies on ponatinib,
its investigational pan-BCR-ABL inhibitor, showing potent inhibition of
all four members of the fibroblast growth factor receptor (FGFR) family
of tyrosine kinases that are abnormally expressed in multiple cancers.
ARIAD scientists are presenting the data this morning at the American
Association for Cancer Research (AACR) Annual Meeting in Orlando,
Florida.
Recent research has established that FGF receptors 1 to 4 are activated
through multiple mechanisms in certain solid tumors and represent
promising targets for antitumor therapy. The new data on ponatinib
demonstrate potent activity against a broad range of tumor cells
activated by all four FGFRs, in vitro and in vivo. In a
panel of 14 cell lines representing multiple different tumor types
including endometrial, bladder, gastric, breast, lung and colon cancer,
ponatinib potently and selectively inhibited FGFR-mediated signaling and
cell growth. Four other tyrosine kinase inhibitors with FGFR inhibitory
activity that are in clinical development were substantially less
active, and none potently blocked all four FGF receptors.
RIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT(TM) Cell-Signaling Regulation Technology
Date(s): 20-Apr-2011 7:31 AM
For a complete listing of our news releases, please click here
Most Advanced Partnered Programs to Enter Phase 2 Clinical Trials
Maintains Internal Focus on Molecularly Targeted Small-molecule
Anti-cancer Drugs
CAMBRIDGE, Mass., Apr 20, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced execution of
three exclusive out-license agreements for separate aspects of its
ARGENT(TM) cell-signaling regulation technology. The licenses to these
non-core assets provide ARIAD with a combination of equity ownership in
partners, upfront payments, ongoing fees for supply of certain research
reagents, and potential milestone and royalty payments linked to
clinical, regulatory and sales achievements of partners.
The ARGENT technology platform combines chemistry and genetics to allow
specific cell-signaling and gene-expression events to be chemically
activated in whole animals and cultured cells. The technology platform
includes a portfolio of distinct small-molecule "dimerizer" compounds
optimized for specific applications. Dimerizers bring specific proteins
together in cells. The technology is being developed to treat human
disease through cancer vaccines, cell therapy and gene therapy, in each
case featuring small-molecule regulation of cellular activation.
weiter geht die Fahrt nach Norden.........Ach - hier freue ich mich wirklich .......und wohl kein Ende in Sicht..............
ARIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD to Webcast Conference Call on Second Quarter 2011 Financial Results
Date(s): 14-Jul-2011 7:35 AM
For a complete listing of our news releases, please click here
CAMBRIDGE, Mass., Jul 14, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Tuesday, August 2, 2011. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. Senior management will discuss
the Company's financial results as of June 30, 2011, key corporate
objectives and additional corporate activities. The Company will
announce the highlights of these topics in a press release to be issued
before the market opens on August 2, 2011 prior to the conference call.
The live webcast can be accessed by visiting the investor relations
section of the Company's website at investor.ariad.com.
The call can be accessed by dialing 866-730-5765 (domestic) or
857-350-1589 (international) five minutes prior to the start time and
providing the pass code 69698816. A replay of the call will be available
on the ARIAD website approximately two hours after completion of the
call and will be archived for three weeks
bei Ariad.com nachlesbar unter news
und im September bei den Roeadshows gehen wir auf die 20 USD - freue nich schon
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
58 | ARIAD Pharmaceuticals Inc. | JoWu81 | Card60 | 25.04.21 01:33 | ||
3 | 46 | Ariad Pharmaceuticals Inc. A real hot stock! | FernandeZ | FernandeZ | 25.04.21 00:53 | |
18 | 4.875 | Ariad Pharmaceuticals - der letzte Thread | steven-bln | vstrecker | 25.04.21 00:38 | |
23 | 3.206 | Ariad Pharmaceuticals-Neu | Heron | Heron | 04.12.18 18:56 | |
36 | 9.311 | Ariad Pharma on the Top | MasterbrokerUSA | MasterbrokerUSA | 26.09.16 18:45 |